Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus,Expert Review of Clinical Immunology

当前位置： X-MOL 学术 › Expert Rev. Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2024-01-08 , DOI: 10.1080/1744666x.2023.2268284
Noémie Gensous _{1,

2} , Estibaliz Lazaro _{2,

3} , Patrick Blanco _{2,

4} , Christophe Richez _{2,

5}

Affiliation

Type 1 interferons (IFNs) play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) and various type I IFNs targeting therapeutic approaches have been developed. Anifrolumab, a ...

中文翻译：

Anifrolumab：欧盟批准的首个生物制剂，不限于疾病活动度较高的患者，用于治疗中度至重度系统性红斑狼疮

1 型干扰素 (IFN) 在系统性红斑狼疮 (SLE) 的发病机制中发挥着至关重要的作用，并且已经开发出多种针对 I 型干扰素的治疗方法。阿尼福鲁单抗（Anifrolumab），一种...

更新日期：2024-01-08

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>